Upfront high‑dose chemotherapy combined with autologous stem cell transplantation: Potential survival benefit for patients with high‑risk diffuse large B‑cell lymphoma

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI

Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M and Loeffler M: Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 28:2373–2380. 2010. View Article : Google Scholar : PubMed/NCBI

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI

Vitolo U, Chiappella A, Brusamolino E, et al: A randomized multicenter phase III study for first line treatment of young patients with high risk (AAIPI 2–3) diffuse large B-cell lymphoma (DLBCL): Rituximab (R) plus dose-dense chemotherapy CHOP14/MEGA CHOP14 with or without intensified high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT). Results of DLCL04 trial of Italian lymphoma foundation (FIL). Ann Oncol. 22:1062011.

Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentez N, Peter N, Ehninger G, et al: Conventional chemoimmunotherapy (R-CHOEP)-14 or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol. 29:80022011. View Article : Google Scholar

Stiff PJ, Unger JM, Cook J, Constine S, Couban S, Shea TC, Winter JN, Miller TP, Tubbs RR, Marcellus DC, et al: Randomized phase III U.S./Canadian intergroup trial (Swog S9704) comparing CHOP (+/−) R for eight cycles to CHOP (+/−) R for six cycles followed by autotransplantation for patients with high-intermediate (H-int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol. 29:80012011. View Article : Google Scholar

Le Gouill S, Milpied NJ, Lamy T, Delwail V, Gressin R, Guyotat D, Damaj GL, Foussard C, Cartron G, Maisonneuve H, et al: First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-Cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. J Clin Oncol. 29:80032011. View Article : Google Scholar

Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, et al: Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 369:1681–1690. 2013. View Article : Google Scholar : PubMed/NCBI

The Ministry of Health, Labor and Welfare, . Ethical Guidelines for Medical and Health Research Involving Human Subjects. http://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000080278.pdf

http://www.kmu.ac.jp/hirakata/visit/treatment/medical_section/ketuekishuyounaika.html

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 17:12441999. View Article : Google Scholar : PubMed/NCBI

Kameoka Y, Takahashi N, Ishizawa K, Kato Y, Ito J, Sasaki O, Murai K, Noji H, Hirokawa M, Tajima K, et al: Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. Int J Hematol. 96:624–630. 2012. View Article : Google Scholar : PubMed/NCBI

Kawabata K, Hagiwara S, Takenouchi A, Tanimura A, Tanuma J, Tachikawa N, Miwa A and Oka S: Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: A report of three cases. Intern Med. 48:111–114. 2009. View Article : Google Scholar : PubMed/NCBI

NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Version 1. 2017.https://www.nccn.org/professionals/physician_gls/f_guidelines.asp

Japanese Society of Hematology, . clinical practice guideline. http://www.jshem.or.jp/gui-hemali/table.html

Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI

NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's lymphomas. Version 2. 2016.https://www.nccn.org/professionals/physician_gls/f_guidelines.asp